Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial
Authors
Keywords
-
Journal
LEUKEMIA
Volume 36, Issue 10, Pages 2443-2452
Publisher
Springer Science and Business Media LLC
Online
2022-08-23
DOI
10.1038/s41375-022-01680-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
- (2021) Hagop M. Kantarjian et al. LEUKEMIA
- Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
- (2021) Richard E. Clark et al. Blood Advances
- MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response
- (2021) Eman M Habib et al. Labmedicine
- Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers
- (2021) Vaidehi Krishnan et al. HAEMATOLOGICA
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)
- (2020) Ali G. Turhan et al. LEUKEMIA & LYMPHOMA
- The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML
- (2020) Hanyang Lin et al. BLOOD
- Treatment-free remission in patients with chronic myeloid leukaemia
- (2020) David M. Ross et al. Nature Reviews Clinical Oncology
- MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
- (2020) Wenxiu Xu et al. CANCER SCIENCE
- The role and mechanisms of action of microRNAs in cancer drug resistance
- (2019) Wengong Si et al. Clinical Epigenetics
- MicroRNA signature refine response prediction in CML
- (2019) Raquel Alves et al. Scientific Reports
- miR-145 supports cancer cell survival and shows association with DDR genes, methylation pattern, and epithelial to mesenchymal transition
- (2019) Siddharth Manvati et al. Cancer Cell International
- Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
- (2019) Neil P. Shah et al. LEUKEMIA & LYMPHOMA
- BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
- (2018) Klara Srutova et al. HAEMATOLOGICA
- Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
- (2018) Ingmar Glauche et al. Scientific Reports
- BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
- (2018) Hye-young Song et al. Cancer Medicine
- Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
- (2018) Jacob O'Brien et al. Frontiers in Endocrinology
- Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia
- (2017) Alice Giustacchini et al. NATURE MEDICINE
- miR-708-5p: a microRNA with emerging roles in cancer
- (2017) Nicholas J. Monteleone et al. Oncotarget
- Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
- (2017) Alfonso Quintás-Cardama et al. Cancer Control
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer
- (2016) Alexander A. Svoronos et al. CANCER RESEARCH
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia
- (2016) Lauren Caldemeyer et al. LEUKEMIA & LYMPHOMA
- miRNAs in chronic myeloid leukemia: small molecules, essential function
- (2016) Zofia Litwińska et al. LEUKEMIA & LYMPHOMA
- Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
- (2016) Sheela A. Abraham et al. NATURE
- MicroRNAs in Myeloid Hematological Malignancies
- (2015) Maria Ciccone et al. CURRENT GENOMICS
- The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)
- (2015) CARLA DI STEFANO et al. ONCOLOGY REPORTS
- ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance
- (2014) A.F. Ferreira et al. BLOOD CELLS MOLECULES AND DISEASES
- Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
- (2013) Elias J. Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
- (2013) Philippe Rousselot et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNAs are shaping the hematopoietic landscape
- (2011) U. Bissels et al. HAEMATOLOGICA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate
- (2010) X. Jiang et al. BLOOD
- Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia
- (2010) S. Flamant et al. HAEMATOLOGICA
- Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
- (2010) Amie S. Corbin et al. JOURNAL OF CLINICAL INVESTIGATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
- (2009) Edurne San José-Enériz et al. Molecular Cancer
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation